Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Editas Medicine (EDIT) Retained Earnings (2016 - 2025)

Editas Medicine (EDIT) has disclosed Retained Earnings for 11 consecutive years, with -$1.6 billion as the latest value for Q3 2025.

  • On a quarterly basis, Retained Earnings fell 310997.13% to -$1.6 billion in Q3 2025 year-over-year; TTM through Sep 2025 was -$1.6 billion, a 310997.13% decrease, with the full-year FY2024 number at $268000.0, up 35.35% from a year prior.
  • Retained Earnings was -$1.6 billion for Q3 2025 at Editas Medicine, down from $15000.0 in the prior quarter.
  • In the past five years, Retained Earnings ranged from a high of $522000.0 in Q3 2024 to a low of -$1.6 billion in Q3 2025.
  • A 5-year average of -$577.0 million and a median of -$777.2 million in 2021 define the central range for Retained Earnings.
  • Peak YoY movement for Retained Earnings: plummeted 1700447.92% in 2021, then soared 126.99% in 2025.
  • Editas Medicine's Retained Earnings stood at -$493000.0 in 2021, then tumbled by 630.43% to -$3.6 million in 2022, then soared by 105.5% to $198000.0 in 2023, then soared by 35.35% to $268000.0 in 2024, then tumbled by 605653.36% to -$1.6 billion in 2025.
  • Per Business Quant, the three most recent readings for EDIT's Retained Earnings are -$1.6 billion (Q3 2025), $15000.0 (Q2 2025), and $88000.0 (Q1 2025).